ABCL News
Biotech And Biomimicry Stocks Lighting Up the Market
Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.
24-7 Market News
Biotech And Biomimicry Stocks Lighting Up the Market
Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.
24-7 Market News
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Zacks
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Ocenico Hotel and Congress Center in Rio de Janeiro, Brazil...
Business Wire
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
AbCellera (Nasdaq: ABCL) announced that the Company will present at the Cantor Global Healthcare Conference on September 9, 2026. A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through...
Business Wire
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals' FDA approval and the companies' antibody partnership.read more...
Benzinga
Monday 8/17 Insider Buying Report: ABCL, BPRN
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
At AbCellera Biologics, a filing with the SEC revealed that on Wednesday, Director...
Nasdaq News: Markets
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
AbCellera Biologics Inc. (Nasdaq: ABCL) (AbCellera) today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to...
Business Wire
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.read more...
Benzinga
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.read more...
Benzinga
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
AbCellera Biologics Inc. (Nasdaq: ABCL) (AbCellera) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and...
Business Wire